Enlivex Receives First FDA Approval For Phase2b Trial Of Allocetra For Age-Related Osteoarthritis

The U.S. Food and Drug Administration (FDA) has cleared Enlivex's Investigational New Drug (IND) application for Allocetra, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA).